Get the Stockscreener App
4.13
12.84%
0.47
Pre-market:
4.10
-0.03
-0.73%
Jyong Biotech Ltd stock is traded at $4.13, with a volume of 416.12K.
It is up +12.84% in the last 24 hours and down -85.86% over the past month.
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
See More
Previous Close:
$3.66
Open:
$3.66
24h Volume:
416.12K
Relative Volume:
0.48
Market Cap:
$313.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.56%
1M Performance:
-85.86%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.66
$4.30
1-Week Range:
$3.41
$4.30
52-Week Range:
$2.601
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
4.13 | 278.26M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd Stock (MENS) Latest News
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech Ltd.(NasdaqGM: MENS) added to NASDAQ Biotechnology Index - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry By Investing.com - Investing.com Nigeria
Jyong Biotech in Talks With Funds Interested in Buying Shares - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com
Jyong Biotech in talks with investment funds for purchasing co's ordinary shares - marketscreener.com
Jyong Biotech ‘not aware’ of any material information amid share price movement - TipRanks
Jyong Biotech Responds to Share Price and Volume Movement - The Manila Times
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week LowHere's Why - MarketBeat
Small U.S. Stocks Decrease; Jyong Biotech Falls Furthest - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Small U.S. Stocks Close Lower; Jyong Biotech Falls Furthest - 富途牛牛
Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3%Here's What Happened - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownWhat's Next? - MarketBeat
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2025. - marketscreener.com
Jyong Biotech Shares Becomes Oversold (MENS) - Nasdaq
Jyong Biotech (NASDAQ:MENS) Trading Down 5.9%Here's Why - MarketBeat
Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - MarketBeat
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World
Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World
Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat
Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com
Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView — Track All Markets
Jyong Biotech Expands Regional Partnerships, Signs MOU with - GlobeNewswire
Jyong Biotech (MENS) Stock Analysis Report | Financials & Insights - Benzinga
Jyong Biotech (NASDAQ:MENS) Trading Up 15.1%Here's What Happened - MarketBeat
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha
Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat
Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia
Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Australia
Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - marketscreener.com
Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times
Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan
MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo - CancerNetwork
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa
Jyong Biotech Ltd Stock (MENS) Financials Data
There is no financial data for Jyong Biotech Ltd (MENS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):